A DaSH-Global White Paper

Will Disruptive Innovation Cure Health Care?

Idea in Brief

Book HBR must read.png

All health care industries in the developed world are ailing. The symptoms? Expensive, inconvenient delivery systems that leave more and more consumers dissatisfied. Why? Major health care institutions have "overshot" the level of care most patients need. Researchers and practitioners focus on the most complicated diseases, while paying
insufficient attention to the needs of patients with more common care needs.

The cure? All health care industry players must embrace dlsruptlve innovations: cheaper, simpler more convenient products or services that ultimately let less expensive professionals provide sophisticated service in affordable settings. Consider angioplasty used by cardiologists with

patients who not long ago would have needed invasive costly surgery by open-heart specialists. Or the latest blood glucose meters, which allow diabetic patients to monitor their own health-accurately, conveniently and inexpensively.

We need many more of these disruptive innovations to revitalize the health care industry. Companies that develop them will grow profitably with less invest-
ment. Hospitals and managed-care institutions will stem their financial hemorrhaging. When industry players and consumers join forces to promote affordable, high-quality medical services, everyone will win.

by Clayton M Christensen, Richard Bohmer, and John Kenagy

How is DAX a disruptive Innovation?


A DAX companion is designed first-and-foremost to address a simple UNMET NEED for patients and services: collecting and communicating Outcomes data.


Primarily the companions are for patients to capture data about their illness (or degree of wellness). It will regularly request and collect Patient Reported OUTCOMES (PROs), as well as symptoms data. It may also collect patient reported EXPERIENCE of services (PREMS) as well as the hugely underrported impact on informal carers: friends and family.  Where appropriate it will also collect costing data and be linked into the new generation of bluetooth wearables. It provides essential feedback to USERS and SERVICES on living with a disease, and turns people from passive recepient of care into a co-producers of care, and a vital NEW source of information for better service delivery and RESEARCH.



UNIQUELY - it is designed to be a part of every-day health service delivery. In its disease area it is not replacing any existing service or treatment. It is a SMART low-cost adjunct to primary care, community care or specialist nurse services. 


In Mesothelioma we are working with Mesothelioma UK to provide this low-cost patient and nursing support companion, for every patient in the UK.


In its early incarnations, it fulfills a simple role of putting the patient in-charge of their own data. The technology is cheap and commonplace, its the role the companion plays in integrating into the existing nurse network of services and delivering on digital health that is innovative.


Disruptive technology usually address new needs in a new way, and migrate to those applications were they create real value over time.

A large proportion of health service innovations arrive from the complex, high cost end, via high costly institutions and expensive specialised professionals. These may be technologically innovative, but are unlikely to be disruptive.

DAX instead comes at the problem from the other end of the spectrum, It supports patients AT HOME. Over time the companion will support new ways of working, enabling procedures and interventions to be undertaken in more convenient and less expensive settings that will ultimately disrupt conventional delivery.  


But for now DAX addresses an UNMET NEED with three simple AIMS, to:
1) support Patients at home,
2) to supplement and integrate into existing Community Service Delivery and 3) to provide ONGOING Real World Evidence for Research.


The support for DAX comes from research. DaSH Global work with Patient Advocacy to protect patient data, but also to commercialise it - paying for the DAX companions, and putting monies back into the patient's advocacy groups.


Health services DO NOT ROUTINELY COLLECT patient reported outcomes - but it is increasingly seen as an essential HEOR resource for improving healthcare and is valued by industry. Drug Trial data alone is no longer sufficient for goverments or regulators to justify the high cost of many interventions. 

DaSH Global with leading Patient Advocacy Partners, are plugging disease areas into DIGITAL HEALTH. Good (FAIR) data is the life-blood of a living health-economy.

A DaSH-Global White Paper


Back to top

© 2023 by Dash-Global Ltd. (using WIX)